{
    "Clinical Trial ID": "NCT01095003",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Vinflunine Plus Capecitabine",
        "  Vinflunine plus Capecitabine: Vinflunine 280mg/m\u00b2 as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks",
        "  Capecitabine 825mg/m\u00b2 per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks",
        "INTERVENTION 2: ",
        "  Capecitabine Single-agent",
        "  Capecitabine: Capecitabine 825mg/m\u00b2 per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  female patients",
        "  21 years of age or older",
        "  histologically/cytologically confirmed carcinoma of the breast",
        "  documented locally recurrent or metastatic disease not amenable to curative surgery or radiotherapy",
        "  either one, two or three prior chemotherapy regimens",
        "  prior treatments including both an anthracycline and a taxane and patient no longer candidate for these drugs",
        "  measurable or non-measurable disease according to RECIST 1.1",
        "  Karnofsky performance score of at least 70 %",
        "  adequate haematological, hepatic and renal functions",
        "  ECG without clinically relevant abnormality",
        "Exclusion Criteria:",
        "  known or clinical evidence of brain metastasis or leptomeningeal involvement",
        "  pulmonary lymphangitis or symptomatic pleural effusion",
        "  any serious, concurrent uncontrolled medical disorder",
        "  history of second primary malignancy",
        "  preexisting motor/sensory peripheral neuropathy",
        "  known history of HIV infection",
        "  prior therapy with capecitabine and/or vinca-alkaloids",
        "  history of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or contra indication to any of these drugs",
        "  known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency",
        "  pregnancy or breast feeding"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival",
        "  PFS is defined as time from date of randomization to date of the first documentation of objective tumor progression (according to the Independent Response Review Committee (IRC) and based on RECIST version 1.1) or death due to any cause.",
        "  The PFS was primarily analysed in the Intent-to-treat (ITT) population. Patients lost to follow-up, or without a known record of progression or death at time of analysis had the progression-free survival censored at the date of last tumour assessment or the date of last contact of a follow-up showing no progression, whichever occurs last.",
        "  Time frame: Baseline up to 2 years 7 months",
        "Results 1: ",
        "  Arm/Group Title: Vinflunine Plus Capecitabine",
        "  Arm/Group Description: Vinflunine plus Capecitabine: Vinflunine 280mg/m  as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks",
        "  Capecitabine 825mg/m  per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks",
        "  Overall Number of Participants Analyzed: 384",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  5.6        (5.3 to 6.3)",
        "Results 2: ",
        "  Arm/Group Title: Capecitabine Single-agent",
        "  Arm/Group Description: Capecitabine: Capecitabine 825mg/m  per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks",
        "  Overall Number of Participants Analyzed: 386",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  4.3        (4.1 to 5.6)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 107/383 (27.94%)",
        "  Anaemia 4/383 (1.04%)",
        "  Febrile neutropenia 7/383 (1.83%)",
        "  Haemoytique anaemia 0/383 (0.00%)",
        "  Leukopenia 1/383 (0.26%)",
        "  Neutropenia 6/383 (1.57%)",
        "  Thrombocytopenia 2/383 (0.52%)",
        "  Anginal pectoris 1/383 (0.26%)",
        "  Cardiomyopathy 0/383 (0.00%)",
        "  Ear pain 0/383 (0.00%)",
        "  Abdominal distension 1/383 (0.26%)",
        "  Abdominal pain 6/383 (1.57%)",
        "Adverse Events 2:",
        "  Total: 85/383 (22.19%)",
        "  Anaemia 3/383 (0.78%)",
        "  Febrile neutropenia 2/383 (0.52%)",
        "  Haemoytique anaemia 0/383 (0.00%)",
        "  Leukopenia 0/383 (0.00%)",
        "  Neutropenia 1/383 (0.26%)",
        "  Thrombocytopenia 1/383 (0.26%)",
        "  Anginal pectoris 0/383 (0.00%)",
        "  Cardiomyopathy 1/383 (0.26%)",
        "  Ear pain 1/383 (0.26%)",
        "  Abdominal distension 0/383 (0.00%)",
        "  Abdominal pain 3/383 (0.78%)"
    ]
}